NASDAQ:PTEPolarityte Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Polarityte Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.24 -0.09 (-6.77 %) (As of 07/1/2020 04:00 PM ET) Add Compare Share Today's Range$1.20Now: $1.24▼$1.3450-Day Range$0.82MA: $1.11▼$1.4352-Week Range$0.78Now: $1.24▼$5.79Volume380,600 shsAverage Volume660,288 shsMarket Capitalization$47.70 millionP/E RatioN/ADividend YieldN/ABeta1.68 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingPolarityte has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.40, Polarityte has a potential upside of 335.5% from its current price of $1.24.Amount of Analyst CoveragePolarityte has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesPolarityte has received 122 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPolarityte has received 105 “underperform” votes. (Add your “underperform” vote.)Community SentimentPolarityte has received 53.74% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Polarityte and other stocks. Vote “Outperform” if you believe PTE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPolarityte does not currently pay a dividend.Dividend GrowthPolarityte does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Polarityte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,348.00 in company stock.Percentage Held by InsidersOnly 8.38% of the stock of Polarityte is held by insiders.Percentage Held by InstitutionsOnly 27.34% of the stock of Polarityte is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Polarityte are expected to grow in the coming year, from ($1.58) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Polarityte is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Polarityte is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPolarityte has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.45 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTE Previous Symbol CUSIPN/A CIKN/A Webwww.polarityte.com Phone385-237-2279Debt Debt-to-Equity Ratio0.06 Current Ratio3.70 Quick Ratio3.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.65 million Price / Sales8.44 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.87Profitability EPS (Most Recent Fiscal Year)($3.70) Net Income$-92,490,000.00 Net Margins-1,561.72% Return on Equity-157.30% Return on Assets-116.60%Miscellaneous Employees153 Outstanding Shares38,464,000Market Cap$47.70 million Next Earnings DateN/A OptionableOptionable NASDAQ:PTE Rates by TradingView Receive PTE News and Ratings via Email Sign-up to receive the latest news and ratings for PTE and its competitors with MarketBeat's FREE daily newsletter. Polarityte (NASDAQ:PTE) Frequently Asked Questions How has Polarityte's stock been impacted by COVID-19 (Coronavirus)? Polarityte's stock was trading at $1.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTE stock has increased by 15.9% and is now trading at $1.24. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Polarityte? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Polarityte in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Polarityte. How were Polarityte's earnings last quarter? Polarityte Inc (NASDAQ:PTE) issued its earnings results on Monday, May, 11th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.57) by $0.18. The company earned $0.93 million during the quarter, compared to analyst estimates of $1.27 million. Polarityte had a negative net margin of 1,561.72% and a negative return on equity of 157.30%. During the same period in the prior year, the business earned ($1.18) EPS. View Polarityte's earnings history. What price target have analysts set for PTE? 5 Wall Street analysts have issued 1 year price objectives for Polarityte's stock. Their forecasts range from $3.00 to $8.00. On average, they expect Polarityte's share price to reach $5.40 in the next twelve months. This suggests a possible upside of 335.5% from the stock's current price. View analysts' price targets for Polarityte. Has Polarityte been receiving favorable news coverage? News headlines about PTE stock have been trending very negative on Thursday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Polarityte earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Polarityte. Who are some of Polarityte's key competitors? Some companies that are related to Polarityte include LogicBio Therapeutics (LOGC), Sutro Biopharma (STRO), Verona Pharma (TARA), Axcella Health (AXLA), Surface Oncology (SURF), Cidara Therapeutics (CDTX), Applied Genetic Technologies (AGTC), Erytech Pharma (ERYP), Solid Biosciences (SLDB), X4 Pharmaceuticals (XFOR), Ayala Pharmaceuticals (AYLA), La Jolla Pharmaceutical (LJPC), Outlook Therapeutics (OTLK), Champions Oncology (CSBR) and Gamida Cell (GMDA). View all competitors. What other stocks do shareholders of Polarityte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Polarityte investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Outlook Therapeutics (OTLK), Unum Therapeutics (UMRX), BioNano Genomics (BNGO), Seanergy Maritime (SHIP), Ekso Bionics (EKSO), Matinas BioPharma (MTNB), OrganiGram (OGI) and Titan Pharmaceuticals (TTNP). Who are Polarityte's key executives? Polarityte's management team includes the following people: Mr. David B. Seaburg, Chief Exec. Officer (Age 50, Pay $7.5k)Dr. Edward Winslow Swanson, Chief Translational Medicine Officer & Co-Founder (Age 35, Pay $400k)Mr. Paul Elliot Mann, Exec. OfficerMr. Richard Hague, Pres & COO (Age 60)Mr. Jacob Alexander Patterson, Interim Chief Financial Officer What is Polarityte's stock symbol? Polarityte trades on the NASDAQ under the ticker symbol "PTE." How do I buy shares of Polarityte? Shares of PTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Polarityte's stock price today? One share of PTE stock can currently be purchased for approximately $1.24. How big of a company is Polarityte? Polarityte has a market capitalization of $47.70 million and generates $5.65 million in revenue each year. The company earns $-92,490,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Polarityte employs 153 workers across the globe. What is Polarityte's official website? The official website for Polarityte is www.polarityte.com. How can I contact Polarityte? Polarityte's mailing address is 123 NORTH WRIGHT BROTHERS DRIVE, SALT LAKE CITY UT, 84116. The company can be reached via phone at 385-237-2279 or via email at [email protected] This page was last updated on 7/2/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
